Transgenic Group Inc. (TYO:2342)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Unallocated Adjustment Amount	-6.70M	-6.44M	-6.72M	-5.47M	-13.30M
Drug Discovery Support Business	2.26B	1.90B	2.32B	2.25B	4.77B
Drug Discovery Support Business Growth	19.13%	-18.21%	2.89%	-52.74%	33.03%
Investment and Consulting Business	10.92B	11.12B	10.77B	9.18B	-
Investment and Consulting Business Growth	-1.74%	3.19%	17.32%	-	-
TGBS Business - E-Commerce Business	-	-	-	-	4.70B
TGBS Business - E-Commerce Business Growth	-	-	-	-	-11.05%
TGBS Business - Others	-	-	-	-	3.12B
TGBS Business - Others Growth	-	-	-	-	41.77%
Total	13.17B	13.01B	13.08B	11.43B	12.58B
Total Growth	1.30%	-0.60%	14.47%	-9.12%	13.85%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Japan	13.17B	13.01B	13.08B	11.43B	12.58B
Japan Growth	1.30%	-0.60%	14.47%	-9.12%	13.85%
Total	13.17B	13.01B	13.08B	11.43B	12.58B
Total Growth	1.30%	-0.60%	14.47%	-9.12%	13.85%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 15, 2026

Data Sources Report a data error